Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Real-world impact of initial treatment modality on survival outcomes in patients with stage I-III pancreatic ductal adenocarcinoma.
Authors
Ajay Prakash
Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN;
Ajay Prakash , Joschua Schwanke , Thuy-Hong Le-Kumar , Brooke Patterson , Schelomo Marmor , Christopher Tignanelli , Eric Hans Jensen , Emil Lou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 684)
DOI
10.1200/JCO.2023.41.4_suppl.684
Abstract #
684
Poster Bd #
J9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy vs upfront resection: A challenging choice in resectable pancreatic ductal adenocarcinoma.
First Author: Fatemeh Fekrmandi
Poster
2023 ASCO Annual Meeting
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.
First Author: Bach Ardalan
Poster
2022 ASCO Annual Meeting
Neoadjuvant chemotherapy is associated with improved outcomes in patients with stage 1A and 1B pancreatic cancer undergoing surgery: An NCDB study.
First Author: Noah Rozich
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical relevance of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant modified FOLFIRINOX.
First Author: So Heun Lee